2 Reasons to Buy Exact Sciences Stock, and 1 Reason to Sell
Thanks to its highly sensitive tests that can detect cancer earlier, less invasively, and with more confidence than the alternatives, Exact Sciences (NASDAQ: EXAS) has already made a home for itself in the oncology screening market.
But it's no surprise why investors might be divided about the merit of buying the stock. Its operations are perennially unprofitable, not to mention that its pace of revenue growth is often meandering. Are these blemishes dealbreakers, or are they bumps in the road along the trajectory of a growth stock? Let's look at two arguments in favor of buying Exact Sciences and then consider one point in favor of selling it to find out.
Image source: Getty Images.
Source Fool.com
